All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, March 2, 2021
Home » Blogs » BioWorld MedTech Perspectives » The far East is becoming the wild West for med-tech

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech

The far East is becoming the wild West for med-tech

Feb. 8, 2013
By Omar Ford
No Comments

In October of last year, Medtronic made headlines when it reported that it was going to acquire Changzhou holdings, a China-based company that is a provider of orthopedic devices, for $816 million.

Now the acquisition, in my opinion was perhaps the loudest shot fired in the battle to maintain a dominant presence in China one of the fastest growing emerging markets.

Last month, Stryker responded in kind with its plan to acquire Trauson Holdings, a China-based firm that specializes in products for the spine for $764 million.

After listening to a webinar from Millinneum Research Group, about the Top 10 trends to watch out for in med-tech, the shift in focus to emerging economies came in at number two on the list. But the interesting thing is, the topic of acquisitions into China was also a part of the seventh trend to watch out for, which was Merger & Acquisition Activity Increasing.

In a sense one could argue that the topic was big enough to take up nearly two slots on the trend list. But what this really signifies is that the shift in thinking for firms is starting to become action.

Companies are eager to dip into new markets and in 2013 and I think we're going to see an explosion of firms investing in emerging markets, especially China.

The rules, however, are going to change, and it's not going to be business as usual when vying for regulatory approval. There are going to be cultural differences, and a different approach on securing clearance for a product to get to market.

It's going to be a far different ride, but this presents a new frontier for med-tech companies to explore.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 1.
  • Gloved hand places sample tubes in PCR system

    COVID-19 test makers are adapting for variants

    BioWorld MedTech
    As COVID-19 variants have emerged, so have questions about the effectiveness of tests for infection. While the risk of mutations significantly limiting their...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for March 1.
  • Celltrion-Regkirona-2-9

    Celltrion wins first conditional Korean approval for COVID-19 antibody Regkirona

    BioWorld
    HONG KONG – Celltrion Inc. has received conditional marketing authorization from the Ministry of Food and Drug Safety (MFDS) for its anti-COVID-19 monoclonal...
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing